Articles tagged with Cancer Cells
Researchers at OIST have discovered that certain cancers can 'lose their sense of time' to avoid cellular stress responses. The study highlights the role of USP28 in stabilizing p53, a known tumor suppressor, and how mutations in this protein can disrupt its function.
Researchers mapped NBCn1's structure-function properties to understand how breast cancer cells thrive in hostile environments. The study provides insights into the protein's dynamics and ion transport pathways, paving the way for designing drugs that target this transporter.
A specific protein, RASH3D19, activates the RAS signaling pathway involved in aggressive tumor growth and resistance to KRAS inhibitors. Blocking RASH3D19 improves outcomes in preclinical models, suggesting a potential therapeutic strategy.
Researchers discovered that certain cancers rely on an emergency DNA repair mechanism called break-induced replication to survive. By understanding how this mechanism works, scientists can develop targeted therapies to selectively kill cancer cells while leaving normal cells intact.
Researchers developed a new approach using the microbial protein Archaerhodopsin-3 to induce apoptosis in cancer cells, leading to significant tumor shrinkage when exposed to green light. The findings, published by Okayama University, show great potential for this light-activated molecule as a novel cancer therapy.
Researchers discovered that synthetic stress hormone dexamethasone can combat therapy-resistant breast cancer metastases in mice trials. The drug activates the glucocorticoid receptor, suppressing estrogen receptor production and slowing tumor growth. Further studies are needed to confirm these findings in patients with breast cancer.
Weill Cornell Medicine researchers have discovered a molecular signal that tumors exploit to exhaust T cells meant to destroy them. By silencing this signal, the body's immunity can be revived and cancer-fighting immune cells restored.
Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
Researchers found that apalutamide and finasteride effectively suppressed AML progression in mice and patient-derived cells by inhibiting the androgen hormone pathway. The study provides a novel targetable pathway for leukemia patients, offering a promising new direction for treatment.
Researchers discovered that pancreatic tumors form pseudosynapses, exploiting the body's nervous system to drive tumor growth. Calcium waves triggered by glutamate binding promote metastasis and cancer progression.
Researchers discovered a new subtype of DLBCL, 'Mann-type DLBCL', which is characterized by the presence of a specific sugar called mannose. This sugar promotes the survival and growth of cancer cells, making them resistant to conventional treatments.
Researchers have discovered how key molecules coordinate chromosome alignment in cell division. Dual inhibition of KIF18A and CENP-E selectively kills cancer cells, suggesting a new therapeutic avenue for cancer treatment. This study highlights the importance of targeting specific proteins to develop more effective anticancer therapies.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
Researchers at University of Miami Miller School of Medicine have developed a new combination therapy that shrinks tumors, reduces cancer stem cells and reprograms immune environment to combat hormone-resistant breast cancer. The triple therapy approach targets tumor-associated macrophages, which act like bodyguards for cancer cells.
Researchers have discovered a new way to understand cancer and its vulnerabilities by targeting FSP1, a protein that helps cancer cells survive. The study found that FSP1 inhibitors can effectively reduce the growth of metastatic melanoma cells in lymph nodes.
Scientists at Wake Forest University School of Medicine have discovered a new way to kill cancer cells by blocking their ability to clean up harmful waste. By inhibiting peroxiredoxin-3, researchers found that toxic levels of hydrogen peroxide overwhelm cancer cells, destroying them.
Researchers at Mass General Brigham have developed a strategy to promote antitumor immunity by inducing cancer cells to produce an immune-activating molecule. This approach was shown to reduce tumor growth and improve survival in mouse models of aggressive melanoma, with potential applications beyond cancer therapies.
A University of Delaware student's unexpected rise as a researcher led to critical new insights into human papillomavirus (HPV) and its role in cancer. The study found that specific mutations in HPV proteins may increase cancer risk, paving the way for improved approaches to diagnosing and treating HPV-related cancers.
A new study led by Johns Hopkins Medicine has shown that targeted radiation during surgery can reduce pancreatic cancer recurrence rates to 5%. By targeting the 'Baltimore triangle' near the pancreas, researchers were able to eliminate cancer cells and prevent recurrences.
Researchers found that tumor-associated macrophages produce acetate through a metabolic interaction involving lactate and the lipid peroxidation–ALDH2 pathway. This acetate promotes histone H3 acetylation and epithelial-mesenchymal transition in hepatocellular carcinoma cells, enhancing metastasis.
Researchers at HUN-REN Szegedi Biológiai Kutatóközpont have developed an AI-powered platform for automated 3D cell culture analysis, enabling high-precision screening of cellular models. The technology removes the limitation of throughput in personalized medicine, allowing for fast and accurate analysis of clinical samples.
A new study by Texas A&M University Health Science Center reveals how TFE3 oncofusions hijack RNA to build liquid-like hubs that promote cancer growth. The researchers also created a molecular switch to dissolve these hubs, cutting off tumor growth at its source.
Scientists at UCL have engineered γδT cells to kill slow-growing bowel cancer cells resistant to chemotherapy. The supercharged cells outperformed regular cells, surviving longer and killing cancer cells even when they couldn't be targeted by chemotherapy.
The research team developed a unique alginate-collagen interpenetrating network (IPN) hydrogel system that mimics the mechanical properties of tissues. Fibroblasts cultured on the hydrogels exhibited unprecedented behavioral patterns, including cell aggregation and reprogramming-related gene expression upregulation. The positive feedba...
Researchers at UT Austin have developed a new cancer treatment that uses LED light and SnOx nanoflakes to precisely target cancer cells without harming healthy ones. The treatment achieved remarkable effectiveness in neutralizing colorectal and skin cancer cells, with up to 92% kill rate in just 30 minutes of exposure.
Joanna Wardwell-Ozgo, a Kennesaw State assistant professor, received a $720,000 NIH grant to investigate the hormonal control of cancer. She aims to understand how hormones affect cellular growth and development, with potential implications for disease mechanisms.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
A team at Lund University has discovered a surface protein, SLAMF6, that helps leukemia cells evade the immune system. The researchers developed an antibody to block this mechanism, restoring the immune system's ability to kill cancer cells in laboratory trials and mice.
Researchers at Johns Hopkins University discovered a novel way to boost the natural immune system, which prevents cancer recurrence and improves survival rates. The study used immune-activating agents to stimulate killer T cells and induce the formation of tumor-specific IgG antibodies.
Scientists have created a high-potency IRE1 inhibitor with a unique inhibition mode that targets the unfolded protein response in cancer cells. This compound binds to the kinase pocket of IRE1, allosterically suppressing its RNAse activity and restoring proper protein folding.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A joint team from The University of Osaka revealed that soft particles exhibit unique focusing patterns compared to rigid particles, influencing their focusing behavior. The study provides fundamental insights into the underlying physics, offering a new theoretical model explaining particle behavior under various flow regimes.
Researchers have discovered how Fusobacterium nucleatum binds to human cell receptors CEACAM1 and CEACAM5, which are frequently overexpressed on many types of cancer cells. This binding mechanism is crucial for developing novel antitumor therapies.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
Researchers found that glioblastoma cells in clusters are less deadly than those that disperse from these clusters. The dispersed cells are more plastic and resistant to therapy, making them a major contributor to treatment resistance and poor patient outcomes.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
Scientists used long-read whole-genome sequencing to analyze methylation patterns in urine DNA, identifying bladder cancer. The approach outperformed existing tests in detecting cancer even at low tumour DNA levels.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A team of Japanese researchers has identified shootin1b as a protein that promotes cell migration in glioblastoma, the most common and difficult-to-treat brain tumor. By suppressing abnormal activity of shootin1b, the study suggests a potential target for preventing glioblastoma spread.
A new computational tool called scODIN simplifies single-cell analysis by automating cell type identification in scRNA-seq data. It allows users to define specific cell subsets at different levels of detail and recognizes cells with intermediate phenotypes or transitional states, capturing complexity missed by traditional methods.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
A new study from Mizzou's College of Veterinary Medicine analyzed the effects of radioactive iodine therapy on thyroid cancer in dogs. The research found that tailoring the dose of radiation more precisely for each dog could improve outcomes and potentially lead to more targeted care.
A new study demonstrates the safety and potential benefits of a perioperative combination immune checkpoint blockade in resectable mesothelioma. Patients treated with the regimen lived a median of 28.6 months, with nearly 36% alive and recurrence-free at follow-up.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
Researchers at SMART Alliance for Research and Technology developed a powerful tool to scan thousands of biological samples and detect transfer ribonucleic acid (tRNA) modifications, which help control cell growth and response to diseases. The tool opens up new possibilities for disease research, diagnostics, and treatment development.
Scientists have found a way to stop brain cancer cells from spreading by 'freezing' hyaluronic acid molecules in place. This approach could lead to a new type of treatment for glioblastoma, the most aggressive form of brain cancer.
Researchers discovered that disrupting protein quality control slows tumor growth in rhabdomyosarcoma, a rare and aggressive cancer primarily affecting children. The treatment, which targets the proteostasis network, significantly slowed or stopped tumor growth in mice implanted with human RMS tumors.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
A new study reveals that body cells change their shape to close gaps such as wounds, using a combination of crawling movements and 'purse-string' contractions. The researchers discovered that the endoplasmic reticulum's ability to reorganize in response to edge curvature plays a crucial role in epithelial cell movement.
The ARCHER study aims to determine whether ultra-hypofractionated stereotactic body radiation therapy is non-inferior to hypofractionated radiotherapy in preserving bladder function. Patients will be randomly assigned to receive either 4 weeks of daily or 5 days of ultra-hypofractionated SBRT.
A team of researchers developed a technology that allows them to measure millions of cell-to-cell interactions quickly and affordably. The study shows that this approach can help predict how patients will respond to immunotherapies, laying the foundation for more personalized treatments.
Researchers developed a software fueled by genomics to predict cancer cell behavior, combining genomics technologies with computational modeling. The new 'grammar' enables communication between biology and code, allowing scientists to build digital representations of multicellular biological systems and simulate diseases like cancer.
Research at University of Arizona Health Sciences found PFAS exposure affects gene activity, tied to cancers, neurological disorders, and autoimmune conditions. Changes in miRNA activity indicate potential health risks, suggesting a link between environmental exposures and disease.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
Researchers found that radiation plus immunotherapy induces a systemic anti-tumor immune response in non-small cell lung cancer, even in tumors that do not typically respond to immunotherapy. The combination therapy improved clinical response in patients whose tumors harbor features of immunotherapy resistance.
Scientists developed a material that can stick to tumors, pumping out chemotherapy drugs for days, minimizing impact on healthy tissue. Early results show great promise for reducing clinical treatments and improving patient outcomes.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...